LEXINGTON, Mass. & SYDNEY--(BUSINESS WIRE)--GI Dynamics, Inc. (ASX: GID), a company pioneering the development of effective non-surgical approaches for treating type 2 diabetes and obesity, announced today that data from a previously reported multi-center, randomized, controlled trial evaluating EndoBarrier® Therapy in obese patients with type 2 diabetes were highlighted on Saturday, June 9, 2012, at the American Diabetes Association’s (ADA) 72nd Scientific Sessions in Philadelphia.
